3.07 USD
+0.29 (+10.43%)
3.16 USD
+0.09 (+2.93%)
MEIP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. MEIP has a great financial health rating, but its profitability evaluates not so good. MEIP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MEIP was profitable.
MEIP had a negative operating cash flow in the past year.
MEIP had negative earnings in 4 of the past 5 years.
MEIP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -152.38%, MEIP is not doing good in the industry: 85.95% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -162.03%, MEIP is doing worse than 63.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| ROIC | N/A |
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MEIP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
MEIP has less shares outstanding than it did 1 year ago.
MEIP has more shares outstanding than it did 5 years ago.
MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 19.34 indicates that MEIP is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.34, MEIP belongs to the top of the industry, outperforming 92.05% of the companies in the same industry.
MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.34 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
MEIP has a Current Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MEIP (16.78) is better than 92.05% of its industry peers.
A Quick Ratio of 16.78 indicates that MEIP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.78, MEIP belongs to the top of the industry, outperforming 92.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.78 | ||
| Quick Ratio | 16.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 157.67% over the past year.
The Revenue for MEIP has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, MEIP shows a very strong growth in Revenue. The Revenue has been growing by 67.72% on average per year.
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MEIP will show a very negative growth in Earnings Per Share. The EPS will decrease by -67.16% on average per year.
MEIP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.04% yearly.
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 1.15 indicates a rather cheap valuation of MEIP.
Based on the Price/Earnings ratio, MEIP is valued cheaply inside the industry as 99.45% of the companies are valued more expensively.
MEIP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.37.
MEIP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.15 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MEIP's earnings are expected to decrease with -37.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
5. Dividend
5.1 Amount
No dividends for MEIP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.07
+0.29 (+10.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner Change285.14%
Ins OwnersN/A
Ins Owner Change0%
Market Cap100.82M
Revenue(TTM)N/A
Net Income(TTM)-31.66M
Analysts43.33
Price Target6.12 (99.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.15 | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.16 | ||
| P/tB | 5.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.67
EY86.97%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.78 | ||
| Quick Ratio | 16.78 | ||
| Altman-Z | 19.34 |
F-Score2
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
EBIT growth 1Y-200.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A
MEI PHARMA INC / MEIP FAQ
What is the fundamental rating for MEIP stock?
ChartMill assigns a fundamental rating of 4 / 10 to MEIP.
What is the valuation status of MEI PHARMA INC (MEIP) stock?
ChartMill assigns a valuation rating of 2 / 10 to MEI PHARMA INC (MEIP). This can be considered as Overvalued.
What is the profitability of MEIP stock?
MEI PHARMA INC (MEIP) has a profitability rating of 0 / 10.
What are the PE and PB ratios of MEI PHARMA INC (MEIP) stock?
The Price/Earnings (PE) ratio for MEI PHARMA INC (MEIP) is 1.15 and the Price/Book (PB) ratio is 5.16.
What is the financial health of MEI PHARMA INC (MEIP) stock?
The financial health rating of MEI PHARMA INC (MEIP) is 9 / 10.